EN DE
Watch Allogene Therapeutics Inc for free: we tell you when fair value or trend changes.
Data-driven stock valuation

Allogene Therapeutics Inc (ALLO) fair value: what the stock is really worth

As of Oct 23, 2026: fair value (intrinsic value) of Allogene Therapeutics Inc stock $0.33, price $1.25, upside -73.5%, quality 32 out of 100. Rating: strongly overvalued. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.

  1. Fair value above price? No
  2. Good quality? No
  3. Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free

Healthcare · US · ISIN US0197701065

AT Allogene Therapeutics Inc logo Thin data Oct 20, 2026

Allogene Therapeutics Inc

ALLO · US

Weakest SetupStrongly overvalued and low quality.

Our calculation puts a fair price 73% below what the stock costs today.

Insider activity 46/100
Fair value $0.3315 · Strongly overvalued (−73.5%)
Quality 32/100
Weak Growth (revenue 3y −91.7 %/yr in USD)
Negative free cash flow
Trails peers (1/6)
Narrow moat 16/100
Thin data
⚠ Dilution
Watch Allogene Therapeutics Inc for free: we tell you when fair value or trend changes. Watch for free

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

$27.64 $0.9528 Fair Value $0.3315 Jul 2021 Oct 2026

White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Oct 20, 2026.

How to read this chart

60‑month range $0.9528 – $27.64 · fair‑value band $0.2210 – $0.4165 · the $1.25 price screens above the $0.3315 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Oct 20, 2026.

Follow Allogene Therapeutics in your weekly email

Every Wednesday you see whether Allogene Therapeutics is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

Allogene Therapeutics, Inc. a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer and autoimmune diseases.

Show moreShow less

It develops a pipeline of multiple allogeneic CAR T cell product candidates utilizing protein engineering, gene editing, gene insertion, and advanced proprietary T cell manufacturing technologies.

The company is also developing cemacabtagene ansegedleucel (cema-cel), an engineered allogeneic CAR T cell product candidate that targets CD19 for the treatment of large B-cell lymphoma (LBCL). In addition, it develops ALLO-316, an engineered allogeneic CAR T cell product candidate that targets CD70 to treat renal cell carcinoma (RCC); and ALLO-329, an engineered allogeneic CAR T cell product candidate that targets both CD19 and CD70 for the treatment of autoimmune diseases (AID), such as systemic lupus erythematosus (SLE), idiopathic inflammatory myopathies (IIM), and systemic sclerosis (SSc). The company was incorporated in 2017 and is headquartered in South San Francisco, California.

Stock analysis

Allogene Therapeutics Inc (ALLO) currently trades at $1.25, while our model-based Fair Value estimate is $0.3315, 73.5% below the price, so the stock looks overvalued today.

Show more

Valuation

How firm this estimate is: it rests on 1 models at a data quality of 96/100, which puts the data coverage at low.

Scenario range: $0.2210 (bear) to $0.4165 (bull), the price of $1.25 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 32/100 (below-average quality), in the Healthcare sector.

Weak Growth: Revenue is shrinking: the last year, the last three and the last five years are all negative.

Allogene Therapeutics Inc reported revenue of $0 in FY2025 versus $38.5M in FY2021. Reported net income was −$191M in FY2025.

Key figures

Market cap $449M Small · EPS (TTM) $−0.6600 · Return on equity −42.4% · Return on assets (EBIT) −43.1% · Operating margin −1,011% · Revenue (TTM) $4.6M · Free cash flow −$150M · Net debt $31.6M.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 16 out of 100 (medium confidence).

What moves the price

The share trades about 59% below its 52-week high and 19% above its 52-week low, currently below its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at 2% fair-value upside, at −73%, ALLO screens richer than that median.

Fair Value models

Bear $0.2210 Fair Value $0.3315 Bull $0.4165
Price $1.25 · Upside -73.5%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above starts from their evidence-weighted blend, not from a single model. In cyclical trough or peak years, after dilution or a stock split it is adjusted afterwards, so it can sit above or below the models. Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds. Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Best data coverage
NCAV (Graham) $0.2600 $0.3900 $0.4900 52
All 1 models by family
Asset-Based
NCAV (Graham) $0.2600 $0.3900 $0.4900 52

The fair value above starts from this blend and is adjusted for dilution from new shares.

Open the full fair value analysis →

Quality Score breakdown

Overall quality 32/100

It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.

Profitability 0
How much profit the company makes from its sales and capital
Quality Growth 37
Are margins and returns getting better?
Cashflow 19
Do the profits arrive as real cash?
Financial strength 60
Debt, balance sheet and risk of trouble
Investment 100
Does it invest with discipline instead of growing at any price?
Low Volatility 50
How calm the share price moves, does not count
Momentum 26
Price trend of the last 3 to 12 months, does not count
Near the 52-week high 24
Distance to the 52-week high, does not count
New shares 0
Buys back shares or issues new ones?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 0/100
Revenue is shrinking: the last year, the last three and the last five years are all negative.
Revenue growth 1 year
−76.8%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−91.7%
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
−673.5% (2020) → −1,241,813.6% (2024)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
not computed

ALLO screens overvalued: fair value 73% below the price. Compare with Vertex Pharmaceuticals Incorporated →

Earlier news

News mood ⓘNews mood, the average tone of recent news (97 articles), rated against how stocks are usually covered. 🚀 Hype = unusually upbeat · 🙂 Positive = above average · 😐 Neutral = typical · 🙁 Negative = below average · 😨 Very negative = unusually downbeat. It reflects the tone of coverage, not our valuation. Neutral
Recent news coverage is roughly neutral, about typical for how stocks are covered.

Compare Allogene Therapeutics Inc with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Biotechnology · 593 stocks

Beats the industry median on 1/5 measures
Overall it trails its industry peers.
Valuation
Quality Score 32 · Bottom 25%
Fair Value upside −73.5% · Bottom 25%
Profitability
Return on assets −45.9% · Bottom 25%

Valuation Multiplesvs Biotechnology median · lower = cheaper

P/B 1.53× · Cheaper than median
P/S (12 months) 96.70× · Priciest 25%

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Biotechnology stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value Compare
Regeneron Pharmaceuticals, Inc REGN $805.67 $1,275 +58% vs ALLO
Vertex Pharmaceuticals Incorporated VRTX $535.17 $588.69 +10% vs ALLO
Samsung Biologics Co 207940 1,417,000 KRW 1,558,700 KRW +10% vs ALLO
WuXi Biologics (Cayman) Inc 2269 HK$49.40 HK$54.34 +10% vs ALLO
argenx SE ARGX $890.05 $908.40 +2% vs ALLO
Alnylam Pharmaceuticals, Inc ALNY $225.10 $217.88 −3% vs ALLO
CSL Limited CSL A$196.08 A$178.71 −9% vs ALLO
BeOne Medicines AG 6160 HK$231.40 HK$153.62 −34% vs ALLO
Celltrion, Inc 068270 197,600 KRW 74,944 KRW −62% vs ALLO
Royalty Pharma plc RPRX $62.15 $19.01 −69% vs ALLO

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued High-Quality StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend Stocks

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names ⭐ Top Rated 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screenerFilter by region, size and sector Compare toolTwo stocks side by side Extrinsic Value Calculator…Calculator with industry benchmark Peter Lynch Fair Value Formula &…Calculator with industry benchmark
Run the numbers yourself: free valuation calculators
DCF CalculatorP/E Ratio CalculatorPEG Ratio CalculatorGraham NumberPeter Lynch FormulaDDM CalculatorIntrinsic ValueIntrinsic vs Extrinsic ValueP/E Ratio by Sector
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Allogene Therapeutics Inc · Fair Value
$0.3315 −73%Fair Value
Calculator →

Cite: Fair Value Calculator (2026). "Allogene Therapeutics Inc Fair Value". https://www.fairvalue-calculator.com/stock/ALLO

Frequently asked questions

Is Allogene Therapeutics Inc (ALLO) overvalued or undervalued?
As of Oct 20, 2026, our model estimates a fair value of $0.3315 versus a price of $1.25, about −73% upside (overvalued).
What is the fair value of ALLO?
Our model-based fair value for Allogene Therapeutics Inc is $0.3315 (as of Oct 20, 2026), built from audited fundamentals. The current price: $1.25.
What is the quality score of ALLO?
Allogene Therapeutics Inc has a Quality Score of 32/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Allogene Therapeutics Inc (ALLO)?
Our model-based price target is the fair value of $0.3315 (as of Oct 20, 2026) from 1 valuation models. Cautious scenario $0.2210, optimistic scenario $0.4165. It is a calculation from audited fundamentals, not an analyst target.
What is the Allogene Therapeutics Inc stock forecast for 2026?
Our models put fair value at $0.3315, about −73% upside versus a price of $1.25 (overvalued). Cautious scenario $0.2210, optimistic scenario $0.4165. The calculation is refreshed regularly with new filings.
What is the revenue of Allogene Therapeutics Inc (ALLO)?
Allogene Therapeutics Inc reported trailing-twelve-month revenue of about $4.6M (latest available figure, as of Oct 20, 2026).
What is the intrinsic value of Allogene Therapeutics Inc (ALLO)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Allogene Therapeutics Inc it is $0.3315 per share (as of Oct 20, 2026), against a price of $1.25. It is the blended result of 1 valuation models (cash flow, earnings, asset, dividend).
Is Allogene Therapeutics Inc stock overvalued or undervalued in 2026?
As of Oct 20, 2026, ALLO trades above its calculated fair value: price $1.25, fair value $0.3315, a gap of about −73% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of ALLO?
No. The price is what the market pays today ($1.25); the fair value is what the company's own numbers justify ($0.3315). For Allogene Therapeutics Inc the two are $0.9185 per share apart. That gap is exactly why we show both numbers side by side.
How much is Allogene Therapeutics Inc worth?
The market values Allogene Therapeutics Inc at about $449M (market capitalisation, as of Oct 20, 2026). Per share that is $1.25; our models calculate a fair value of $0.3315 per share.
What do the bullish and bearish scenarios say about ALLO?
Our models span a range for Allogene Therapeutics Inc: cautious scenario $0.2210, base $0.3315, optimistic $0.4165 per share (as of Oct 20, 2026, price $1.25). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of Allogene Therapeutics Inc (ALLO)?
Balance-sheet figures for Allogene Therapeutics Inc (as of Oct 20, 2026): return on equity −42.4%. They feed the Quality Score of 32/100, which measures business quality independently of the share price.
How far is ALLO from its 52-week high?
Allogene Therapeutics Inc trades at $1.25, about 59% below its 52-week high of $3.06 and 19% above the low of $1.05 (as of Oct 23, 2026). Distance from the high says nothing about value: that is what the fair value of $0.3315 is for.
Which stocks are comparable to Allogene Therapeutics Inc?
From the same area (Healthcare) we also value Vertex Pharmaceuticals Incorporated, Regeneron Pharmaceuticals, Inc, CSL Limited, argenx SE, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Allogene Therapeutics Inc stock attractive at the current price?
The data as of Oct 20, 2026: price $1.25, calculated fair value $0.3315 (−73%), Quality Score 32/100, from 1 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of ALLO calculated?
We run Allogene Therapeutics Inc through 1 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of $0.3315, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 12.3 % above its aggregate fair value. Allogene Therapeutics Inc itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Allogene Therapeutics Inc (ALLO)?
The closing price on Oct 23, 2026 was $1.25. Our model-based fair value is $0.3315, about −73% upside (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Allogene Therapeutics Inc right now?
The price sits above even our optimistic bull case ($0.4165). The favourable scenario is already priced in. Weak quality (32/100) and above fair value at the same time, the margin of safety is missing on both counts. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution. A fairly wide model range ($0.2210 to $0.4165) leaves room in how you read the outcome.

Key figures of Allogene Therapeutics Inc

How large is the market capitalisation of Allogene Therapeutics Inc (ALLO)?
The market capitalisation of Allogene Therapeutics Inc is $449M. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What are the earnings per share of Allogene Therapeutics Inc (ALLO)?
Earnings per share at Allogene Therapeutics Inc are $−0.6600. Earnings per share over the last twelve months: total profit spread across every single share.
What is the return on equity of Allogene Therapeutics Inc (ALLO)?
The return on equity (ROE) of Allogene Therapeutics Inc is −42.4% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Allogene Therapeutics Inc (ALLO)?
On an EBIT basis the return on assets of Allogene Therapeutics Inc is −43.1% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Allogene Therapeutics Inc (ALLO)?
The operating margin of Allogene Therapeutics Inc is −1,011% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How much free cash flow does Allogene Therapeutics Inc (ALLO) generate?
The free cash flow of Allogene Therapeutics Inc is −$150M (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net debt does Allogene Therapeutics Inc (ALLO) carry?
The net debt of Allogene Therapeutics Inc is $31.6M (fiscal year 2025). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed

Watch Allogene Therapeutics Inc in the live analysis

One click puts Allogene Therapeutics Inc on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 28,000+ stock screener.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.